Chimeric Antibody Composition for Smallpox Passive Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for protecting against smallpox, particularly in the context of bioterrorism, are inadequate due to the decline in immunity from vaccination and the limitations of existing vaccines, which are contraindicated for certain populations and lack rapid effectiveness in providing protective immunity.
Innovation Solution
Development of a composition comprising non-blood derived antibodies, such as chimeric or humanized antibodies, that specifically bind to epitopes on both the MV and EV forms of the smallpox virus, providing passive immunity through a combination of anti-MV and anti-EV neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional smallpox vaccines are used, then immunity protection is provided, but they are contraindicated for certain populations and lack rapid effectiveness
Solution Approach 1:
The patent uses monoclonal antibodies as intermediary substances to transfer immunity protection without requiring vaccination. These antibodies directly neutralize the smallpox virus by binding to epitopes on both MV and EV forms, serving as a mediator that provides protection to populations who cannot receive conventional vaccines, including immunocompromised individuals and pregnant women
Solution Approach 2:
The patent changes the parameter of immunity delivery from active vaccination (requiring immune system response) to passive antibody administration (immediate effect). This parameter change enables rapid effectiveness within hours rather than weeks, and makes the treatment applicable to all populations regardless of immune status or vaccination contraindications
2Reliability
If vaccination immunity is relied upon, then protection against smallpox is achieved, but immunity declines over time
Solution Approach 1:
The patent applies preliminary action by administering monoclonal antibodies before smallpox exposure or immediately after exposure to prevent virus replication. This pre-established passive immunity eliminates the time lag associated with developing active immunity through vaccination, providing immediate protection when needed most
Solution Approach 2:
The monoclonal antibodies serve as a temporary intermediary that bridges the gap between declining vaccination immunity and the need for immediate protection. These antibodies provide bridge immunity that can be administered to boost protection in individuals whose vaccination-induced immunity has waned over time
3Measurement precision
If a single antibody targeting one virus form is used, then specific neutralization is achieved, but broad-spectrum protection is insufficient
Solution Approach 1:
The patent merges two separate monoclonal antibodies into a single composition: one antibody specifically targets epitopes on the MV (mature virion) form of smallpox virus, while the other specifically targets epitopes on the EV (enveloped virion) form. This combination provides broad-spectrum protection against both infectious forms of the virus while maintaining high specificity for neutralization
Solution Approach 2:
The patent creates a universal antibody composition that functions against multiple virus forms (MV and EV) through the combined action of two monoclonal antibodies. Each antibody maintains its specific binding precision to its target epitope, while the composition as a whole achieves multi-functionality by protecting against both viral forms that constitute the complete smallpox infectious cycle
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody composition effectively imparts prophylactic and therapeutic passive immunity against smallpox, addressing the limitations of existing vaccines by providing rapid and broad-spectrum protection across various populations, including those contraindicated for conventional vaccines.
Implementation Method 1
a non-blood derived antibody, or fragment thereof, wherein the antibody or the fragment immunospecifically binds to an epitope found on an MV form of the smallpox virus
Data Source
AI summary
The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.